HAC (Russian)
RSCI (Russian)
EBSCO
DOI (USA)
Ulrichsweb (Ulrich’s Periodicals Directory)
Scientific Indexing Services

Diagnosis and treatment of familial Mediterranean fever (periodic disease)

DOI: https://doi.org/10.29296/25877305-2022-01-12
Issue: 
1
Year: 
2022

Associate Professor V. Skvortsov(1), MD; Associate Professor I. Statsenko(1), Candidate of
Medical Sciences, M. Kirina(2); E. Golieva(1); G. Malyakin(1) (1)Volgograd State Medical University,
Ministry of Health of Russia (2)Volgograd Regional Clinical Hospital One

Familial Mediterranean fever (FMF; periodic disease) is an autosomal recessive disease, the features of which are recurrent inflammatory episodes, abdominal pain, fever, and arthritis. FMF is divided into two phenotypes. The most accurate diagnostic method is molecular genetic testing that includes a single-gene study, utilization of a multigene panel, and more whole- genome testing. The main therapy for the disease includes colchicine; its acute episodes are treated with nonsteroidal anti-inflammatory drugs and infusion therapy. Drugs, such as anakinra, rilonacept, and canakinumab, are used to treat colchicine-resistant FMF patients. The article describes the clinical case of a female patient with FMF.

Keywords: 
therapy
familial Mediterranean fever
colchicine
anakinra
rilonacept
canakinumab



References: 
  1. Salehzadeh F., Emami D., Zolfegari A.A. et al. Familial Mediterranean fever in northwest of Iran (Ardabil): the first global report from Iran. Turk J Pediatr. 2008; 50 (1): 40–4.
  2. Ozen S., Demirkaya E., Erer B. et al EULAR recommendations for the management of familial Mediterranean fever. Ann Rheum Dis. 2016; 75: 644–51. DOI: 10.1136/annrheumdis-2015-208690
  3. Haute Autorité de Santé. Protocole National de Diagnostic et de Soins. Fièvre Méditerranéenne Familiale. Saint-Denis La Plaine: HAS, 2013.
  4. Bashardoust B. Familial Mediterranean fever; diagnosis, treatment, and complications. J Nephropharmacol. 2015; 4 (1): 5–8.
  5. Shohat M., Adam M.P., Ardinger H.H. et al. Familial Mediterranean fever. GeneReviews® [Internet], 2016.
  6. Pras M. Familial Mediterranean fever: from the clinical syndrome to the cloning of the pyrin gene. Scand J Rheumatol. 1998; 27 (2): 92–7. DOI: 10.1080/030097498440949
  7. Ozçakar Z.B., Yalçinkaya F., Cakar N. et al. Application of the new pediatric criteria and Tel Hashomer criteria in heterozygous patients with clinical features of FMF. Eur J Pediatr. 2011; 170 (8): 1055–7. DOI: 10.1007/s00431-011-1404-y
  8. Kondi A., Hentgen V., Piram M. et al. Validation of the new paediatric criteria for the diagnosis of familial Mediterranean fever: data from a mixed population of 100 children from the French reference centre for auto-inflammatory disorders. Rheumatology (Oxford). 2010; 49 (11): 2200–3. DOI: 10.1093/rheumatology/keq252
  9. Moradian M.M., Babikyan D., Banoian D. et al. Comprehensive analysis of mutations in the MEFV gene reveal that the location and not the substitution type determines symptom severity in FMF. Mol Genet Genomic Med. 2017; 5 (6): 742–50. DOI: 10.1002/mgg3.336
  10. El Hasbani G., Jawad A., Uthman I. Colchicine: An ancient drug with multiple benefits [published online ahead of print, 2020 Oct 23]. Curr Pharm Des. 2020. DOI: 10.2174/1381612826666201023144320
  11. Slobodnick A., Shah B., Krasnokutsky S. et al. Update on colchicine, 2017. Rheumatology (Oxford). 2018; 57 (suppl_1): i4–i11. DOI: 10.1093/rheumatology/kex453
  12. Ben-Zvi I., Kukuy O., Giat E. et al. Anakinra for Colchicine-Resistant Familial Mediterranean Fever: A Randomized, Double-Blind, Placebo-Controlled Trial. Arthritis Rheumatol. 2017; 69 (4): 854–62. DOI: 10.1002/art.39995
  13. Babaoglu H., Varan O., Kucuk H. et al. On demand use of anakinra for attacks of familial Mediterranean fever (FMF). Clin Rheumatol. 2019; 38 (2): 577–81. DOI: 10.1007/s10067-018-4230-z
  14. Hashkes P.J., Spalding S.J., Giannini E.H. et al. Rilonacept for colchicine-resistant or -intolerant familial Mediterranean fever: a randomized trial. Ann Intern Med. 2012; 157 (8): 533–41. DOI: 10.7326/0003-4819-157-8-201210160-00003
  15. Hashkes P.J., Spalding S.J., Hajj-Ali R. et al. The effect of rilonacept versus placebo on health-related quality of life in patients with poorly controlled familial Mediterranean fever. Biomed Res Int. 2014; 2014: 854842. DOI: 10.1155/2014/854842
  16. Alpa M., Roccatello D. Canakinumab as rescue therapy in familial Mediterranean fever refractory to conventional treatment. Drug Des Devel Ther. 2015; 9: 1983–87. DOI: 10.2147/DDDT.S69117